An Analysis of the Generic Pharmaceutical Industries in ...

Hatch-Waxman forces brand-name drug manufacturers such as GNB to face significant risks from a growing lineup of generic drug manufacturers. On the other hand, by using GNB’s safety and efficacy studies, generic drug manufacturers like Aldrin need to invest little to challenge patents. ................
................